How to Get Evenity (Romosozumab) in Massachusetts

Romosozumab (brand name Evenity, manufactured by Amgen and marketed with UCB) is a monoclonal antibody that inhibits sclerostin, a protein that normally suppresses bone formation. It is FDA-approved for osteoporosis in postmenopausal women at high fracture risk, given as two 105 mg subcutaneous injections (210 mg total) once monthly for 12 months, followed by an antiresorptive medication.

Getting Evenity in Massachusetts is not primarily a prescribing-access problem. Any physician, nurse practitioner, or physician assistant licensed in the state can write the prescription, including through telehealth. The real bottleneck is administrative: baseline labs and cardiovascular clearance, prior authorization documentation, and specialty pharmacy or buy-and-bill logistics. This guide walks through each step and separates what is fixed by federal label and clinical guideline from what changes by insurer, plan year, or pharmacy contract.

The direct answer

Massachusetts residents can be evaluated for Evenity in person or by telehealth with an MD, DO, NP, or PA licensed in the state, but the injections themselves must be given in a clinical setting. Coverage generally requires prior authorization documenting a qualifying T-score or fragility fracture, cardiovascular clearance, and usually a prior bisphosphonate trial or documented intolerance. The federal label facts (indication, dose, black box warning) are stable; the insurer-specific rules, processing times, and out-of-pocket costs are not, and should be confirmed directly with the plan and pharmacy before assuming any number quoted online still applies.

Who can prescribe Evenity in Massachusetts

Massachusetts allows nurse practitioners to practice with full authority, without a mandated collaborative agreement with a physician; physician assistants prescribe under a supervisory arrangement. Both scope-of-practice details are set by state licensing boards and can change, so a prescriber's actual authority should be confirmed with their license type and the current Massachusetts Board of Registration in Nursing or Medicine rules rather than assumed from this article.

In practice, rheumatologists, endocrinologists, and orthopedic specialists prescribe Evenity most often, with primary care and geriatric practices initiating it as well, particularly where specialist wait times run long. The prescriber needs to be comfortable reading DXA and FRAX results and needs a plan for the antiresorptive medication that follows the 12-month course.

Massachusetts telehealth rules, updated by the state's telehealth parity requirements, permit prescribing non-controlled medications like romosozumab without a prior in-person visit (Mass.gov telehealth information). A telehealth visit can cover history review, lab interpretation, and prescribing, but the injection itself requires an in-person visit to a clinic, infusion site, or a home health service.

Labs and imaging before the first dose

Before prescribing, clinicians typically order:

• Serum calcium (corrected for albumin), since romosozumab can worsen hypocalcemia
• 25-hydroxyvitamin D, with most guidelines targeting sufficiency before starting an anabolic bone agent
• Comprehensive metabolic panel including creatinine and eGFR
• Serum phosphorus and magnesium
• Intact PTH to rule out primary hyperparathyroidism
• Bone turnover markers (P1NP, CTX) as a baseline for later monitoring

Imaging typically required:

• A DXA scan, generally within the past two years, showing a T-score consistent with osteoporosis, or osteopenia with a qualifying fracture-risk assessment or prior fragility fracture
• A lateral vertebral assessment or spine X-ray to identify existing vertebral fractures, which strengthens both the clinical case and the prior authorization request

Guideline bodies including the Endocrine Society and AACE recommend anabolic therapy as a first-line option, ahead of bisphosphonates, in patients at very high fracture risk (recent fracture, markedly low T-score, or high fracture-probability score). Readers considering this sequencing should review the current versions of professional endocrinology guidelines with their prescriber, since guideline thresholds are periodically revised.

Vitamin D deficiency is generally corrected before the first dose. The specific repletion regimen and target level should come from the prescriber, not from an online guide, since dosing is individualized to baseline level and renal function.

The cardiovascular warning is not optional screening

Romosozumab carries an FDA boxed warning for cardiovascular risk. According to its prescribing information, romosozumab is contraindicated in patients with a history of myocardial infarction or stroke in the prior year, and requires careful benefit-risk assessment in those with additional cardiovascular risk factors. This represents a formal contraindication rather than an optional precaution.

Before prescribing, a Massachusetts clinician should document:

• Cardiovascular history (MI, stroke, TIA, peripheral vascular disease)
• Blood pressure
• A recent lipid panel
• An estimate of cardiovascular risk (such as ASCVD risk score)

A large randomized trial comparing romosozumab with alendronate (the ARCH trial) reported a higher rate of major cardiovascular events in the romosozumab arm during the active-comparator period. Because the exact event rates cited in secondary summaries of this trial vary and the underlying identifier could not be independently verified for this draft, readers and prescribers should confirm the current numbers against the FDA label and the primary trial publication rather than relying on a specific percentage repeated online.

How prior authorization generally works

Massachusetts Medicaid (MassHealth) and the major commercial plans operating in the state cover Evenity with prior authorization when severe osteoporosis criteria are met. The general shape of most payers' criteria includes:

• A confirmed osteoporosis diagnosis
• DXA results or a documented fragility fracture consistent with high fracture risk
• Documentation of a bisphosphonate trial, failure, intolerance, or contraindication (the specific duration required varies by plan)
• Cardiovascular clearance consistent with the label's contraindication window
• Lab confirmation that calcium is normal and vitamin D has been repleted

Verification checklist: what is stable versus what you must confirm today

Use this to separate facts that come from the FDA label and national guidelines (stable, does not depend on your insurer or the calendar) from facts that are plan-specific, date-specific, or pharmacy-specific and must be re-verified before you rely on them.

Stable, federal/clinical facts (verify against the label or guideline, not a plan year):

• FDA-approved indication: osteoporosis in postmenopausal women at high fracture risk
• Dose and schedule: two 105 mg subcutaneous injections monthly for 12 months
• Boxed warning: contraindicated within 12 months of MI or stroke
• Treatment is time-limited and must be followed by an antiresorptive agent
• Baseline labs generally required: calcium, vitamin D, renal function, PTH, bone turnover markers
• Massachusetts allows telehealth initiation of non-controlled prescriptions, with injections given in person

Date-sensitive facts you must confirm before acting (insurer, pharmacy, or state-program specific):

• Your specific plan's prior authorization criteria and required bisphosphonate trial length
• Current MassHealth or commercial PA processing timelines
• Which specialty pharmacy your plan requires (CVS Specialty, Accredo, OptumRx, or another)
• Your plan's specialty-tier copay or coinsurance amount for this drug
• Whether Amgen's copay assistance or patient assistance programs currently apply to your coverage type, and their current income and eligibility thresholds
• Cash price if paying without insurance, which changes over time and by pharmacy
• Whether your prescriber's practice uses buy-and-bill (medical benefit) versus a specialty pharmacy (pharmacy benefit), which changes your billing pathway

If a number in this article or elsewhere online (a copay figure, a turnaround time, a cash price) is not dated to the current month, treat it as a starting point for a phone call to your plan and pharmacy, not as a fact to plan around.

A common reason for denial is insufficient documentation of a prior bisphosphonate trial or intolerance. Clinic notes that name the specific bisphosphonate, duration of use, and reason for discontinuation (GI intolerance, inadequate response, contraindication) strengthen the request.

Where to fill an Evenity prescription in Massachusetts

Evenity is a specialty biologic that requires refrigerated cold-chain handling. Patients typically obtain it through one of three channels:

A specialty pharmacy designated by the insurer (commonly CVS Specialty, Accredo, or OptumRx), which coordinates prior authorization and shipping, either to the patient or the administering clinic.

Buy-and-bill through the prescriber's office, where the practice purchases the drug through a distributor and bills the medical benefit for both the drug and the administration visit. This is common in rheumatology and endocrinology practices and keeps the prescription and injection at the same visit.

A 503A-licensed pharmacy in Massachusetts, regulated by the state Board of Registration in Pharmacy, which may dispense the commercially manufactured product on a patient-specific prescription. Because romosozumab is a biologic, a 503A pharmacy dispenses the manufactured product; it does not compound the drug itself.

Most patients receive the injection in a clinical setting, with two sequential subcutaneous injections given at the same visit.

What happens after the 12-month course

Romosozumab's anabolic effect is time-limited. Bone formation markers return toward baseline after the treatment course ends, and without a follow-on antiresorptive medication, bone density gains are not maintained over time. Clinicians commonly transition patients to denosumab, zoledronic acid, or an oral bisphosphonate, with the specific choice depending on fracture risk, kidney function, and patient preference around injection frequency. Denosumab discontinuation in particular carries its own rebound vertebral fracture risk and should not be stopped without a bridging plan; this is a separate clinical decision that a treating clinician needs to manage directly rather than something a general access guide can specify. The sequencing plan should ideally be set before starting romosozumab, not decided at month 12, since gaps in antiresorptive coverage can undo the gains made during the anabolic phase.

Cost and financial assistance

Evenity's list price and typical out-of-pocket costs are not stable numbers this article can responsibly quote. Under Medicare Part B, romosozumab given in a provider's office is billed as a medical benefit, and patients generally owe coinsurance after meeting the Part B deductible; the exact dollar amount depends on current Medicare rates and any supplemental coverage. Commercial plan copays depend on specialty-tier placement, which varies by plan and plan year. MassHealth patients approved through prior authorization typically have low cost-sharing, but the exact amount should be confirmed with MassHealth directly.

Amgen offers patient support programs, including copay assistance for eligible commercially insured patients and a safety-net program for uninsured or underinsured patients based on income eligibility. Program terms, eligibility thresholds, and covered amounts change and should be confirmed directly with Amgen or the prescriber's office rather than assumed from a general guide.

Evidence boundary: what is established and what is not

Established by the FDA label and randomized trial evidence: romosozumab increases bone density and reduces vertebral fracture risk in postmenopausal women at high fracture risk, and carries a boxed cardiovascular warning that restricts use after a recent MI or stroke.

Plausible but not something this article can quantify precisely: the exact magnitude of cardiovascular risk elevation and the exact percentage fracture-risk reduction reported in specific trials. These numbers are widely cited online, sometimes inconsistently, and should be checked against the current FDA label and the original trial publications before being used in a clinical or coverage discussion.

Not established or not something a general access article can responsibly state: individualized dosing decisions, whether a specific patient qualifies for prior authorization, current copay amounts, current MassHealth or commercial processing timelines, and cash price. These depend on the individual's plan, the current plan year, and direct confirmation with the insurer and pharmacy.

Common questions

Do I need to see a specialist to start Evenity in Massachusetts? Not necessarily. Endocrinologists and rheumatologists prescribe it most often, but an experienced primary care physician, NP, or PA can also prescribe within their scope, provided they can interpret the required labs and imaging and manage the cardiovascular screening.

Can the whole process happen by telehealth? The evaluation, lab review, and prescribing can happen by telehealth under Massachusetts's telehealth rules. The injections require an in-person visit.

What is the most common reason a prior authorization is denied? Insufficient documentation of a prior bisphosphonate trial, intolerance, or contraindication is a frequently cited reason across payers; the specific documentation standard varies by plan and should be confirmed with the individual insurer.

Does Evenity require ongoing treatment after 12 months? No, and it should not be continued indefinitely. It is followed by a different antiresorptive medication to preserve the bone density gains, decided in advance with the prescriber.

Is Evenity approved for men? Evenity's FDA approval is for postmenopausal women at high fracture risk. Use in men would be off-label, and insurers are unlikely to approve prior authorization for an off-label indication without specific plan policy support.

References

1. Evenity (romosozumab-aqqg) prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761062s000lbl.pdf
2. Massachusetts telehealth information. Mass.gov. https://www.mass.gov/info-details/telehealth
3. Centers for Disease Control and Prevention. Osteoporosis data and statistics. https://www.cdc.gov/osteoporosis/data/index.html

Note for editorial review: this draft removed several specific figures from the prior version (exact ARCH trial cardiovascular event rates, FRAME trial percentage fracture reductions, MassHealth PA turnaround times, WAC and copay dollar amounts, and an attributed quotation from a named physician) because the underlying citations could not be verified as pointing to the correct source material. These should be reinstated only after a reviewer confirms the exact figures against the current FDA label and the primary trial publications, and after the quotation's source is verified or the quotation is removed permanently.